DRI Healthcare Trust will report third-quarter results after the market closes on November 4. Analysts expect EPS of US$0.07 and revenue of US$45.03 million, though the trust’s recent earnings record is mixed.
DRI Healthcare Trust (DHT-U.TO) is scheduled to report results for the quarter ended September 30, 2026, after the market closes on November 4. Its earnings call is set for November 5. One analyst expects EPS of US$0.07, while seven analysts forecast revenue of US$45.03 million, down 7.6% from a year earlier. DRI beat estimates in two of its last four reported quarters. That record leaves room for another beat, but doesn’t make one a sure thing. For more company information, see the DRI Healthcare Trust stock page.
Recent earnings trend
DRI Healthcare Trust
DHT-U.TO
DHT-U.TO
DRI Healthcare Trust
WealthAwesomeMarket cap
$638.67M
Div. yield
3.61%
Div. / share
$0.42
52W high
$13.78
52W low
$10.33
1W change
+0.00%
Beta
0.62
Analyst Price Targets
Based on analyst covering DHT-U · as of Sep 17, 2026
Wall Street analysts forecast DHT-U stock price to rise 158.2% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
US$30.00
+158.2% Upside
Current Price
US$11.62
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on DHT-U's historical volatility
30-Day Vol
43.7%
Annualized
90-Day Vol
37.2%
Annualized
Trend (90d)
-29.0%
Annualized drift
90d Mean
US$10.48
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$11.23 | US$9.65 – US$13.05 |
| 60 trading days | US$10.85 | US$8.76 – US$13.42 |
| 90 trading days | US$10.48 | US$8.07 – US$13.60 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Analyst coverage: 1 analyst(s) cover this name; upcoming EPS consensus is available.
Beat estimates in 2 of the last 4 comparable quarter(s).
| Fiscal period | Report date | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| 2026-09-30 | 2026-11-04 | — | 0.7700 | — |
| 2026-06-30 | 2026-08-07 | 0.1100 | 0.0100 | +1000.0% |
| 2026-03-31 | 2026-05-14 | -0.0200 | 0.0700 | -128.6% |
| 2025-12-31 | 2025-12-31 | 0.1600 | 0.0300 | +433.3% |
| 2025-03-31 | 2025-05-12 | -0.0300 | 0.0900 | -133.3% |
| 2024-12-31 | 2024-12-31 | 0.1200 | -0.2000 | +160.0% |
Investor takeaway: The main question is whether DRI can meet the US$0.07 EPS estimate while managing an expected revenue decline. The trust beat estimates in two of its last four comparable quarters and missed in the other two. In its latest reported quarter, EPS was US$0.11, compared with an estimate of US$0.01. But results have varied, and just one analyst contributes to the current EPS consensus. Investors should also watch DRI’s royalty transactions. The trust said it expected to close a US$316 million purchase of U.S. royalty rights for Parkinson’s drug tavapadon after the drug received FDA approval. The deal could affect the portfolio over time, but the available information doesn’t show how it will affect this quarter’s results.
US$0.07 EPS consensus
One analyst expects third-quarter EPS of US$0.07. Seven analysts forecast revenue of US$45.03 million, a 7.6% year-over-year decline. EPS estimates were unchanged in the 30 days before the report.
Bull case
DRI beat estimates in two of its last four reported quarters, including the June 2026 quarter, when EPS came in at US$0.11 against an estimate of US$0.01. In its second-quarter release, the company also reported record quarterly income, cash receipts and adjusted EBITDA, with an adjusted EBITDA margin of 92%. Investors will also be watching the tavapadon royalty acquisition as they assess DRI’s portfolio and future cash receipts.
Bear case
DRI’s recent results are mixed. It missed estimates in March 2026 and March 2025, and the supplied fundamentals snapshot shows negative trailing-twelve-month EPS and a negative profit margin. Revenue estimates point to a 7.6% year-over-year decline. The estimates also have limits: only one analyst contributes to the EPS consensus, and recent large percentage surprises were based on very small estimates. So a headline beat alone may not tell investors much about the business’s direction.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
